ArticleNPJ Parkinson's disease2026
Characterization of patients with isolated REM sleep behavior disorder and cerebrospinal fluid α-synuclein negativity.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolated REM sleep behavior disorder (IRBD) represents the prodromal phase of synucleinopathies. We investigated the characteristics of IRBD patients who tested negative for misfolded α-synuclein (αsyn) in CSF. CSF αsyn was analyzed by seed amplification assay (SAA) in 191 consecutive patients. Using logistic regression, demographic and clinical variables were compared between subjects with negative (αsyn-) and positive (αsyn+) αsyn. αsyn- occurred in 47 (24.61%) patients who were younger (p = 0.018), had less electromyographic REM sleep activity (p < 0.001), and more frequent normal DAT-SPECT (p < 0.001), normosmia (p < 0.001), major depressive disorder (p < 0.001) and antidepressant use (p < 0.001). After a mean follow-up of 5.35 years, 5 of 47 (10.64%) αsyn- patients and 61 of 144 (42.36%) αsyn+ patients developed Parkinson disease (PD) or dementia with Lewy bodies (DLB). Kaplan-Meier analysis showed αsyn- patients had a lower risk of developing PD and DLB (log-rank test p < 0.001; HR 5.355, 95% CI 1.945-14.742). CSF αsyn- occurs in IRBD patients with lower age, less synucleinopathy biomarkers and lower or delayed risk of developing PD and DLB. The cause of αsyn- in IRBD might include a very early synucleinopathy stage or a non-synucleinopathy condition (e.g., antidepressant side-effect). Our observation in IRBD might be important for design of neuroprotective trials targeting αsyn.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.